SEOUL, November 16 (AJP) - hares of HLB Therapeutics plunged 29.98 percent to 1,635 won in early trading Monday, hitting the daily lower limit after its experimental eye treatment failed to meet the primary endpoint in a US Phase 3 clinical trial.
The company's US subsidiary ReGenTree reported that RGN-259, a treatment for neurotrophic keratitis, failed to show a statistically significant improvement in cure rates compared with a placebo after four weeks of treatment. The rare eye disease damages corneal nerves, reducing sensation and the eye's ability to heal naturally. RGN-259 is an eye drop containing thymosin beta-4, a protein intended to promote tissue repair and nerve regeneration.
HLB Therapeutics said it received the preliminary results from its contract research organization on Nov. 13 and plans to analyze secondary endpoints and patient subgroup responses before deciding its next steps. As of 9:41 a.m., the stock remained at the daily lower limit of 1,635 won, down 700 won from its previous close of 2,335 won, according to Korea Exchange data.
Tags : HLBTherapeutics, HotStock, KOSDAQ, KoreanStockMarket, ClinicalTrial, Phase3Trial, RGN259, NeurotrophicKeratitis, Biotechnology
The company's US subsidiary ReGenTree reported that RGN-259, a treatment for neurotrophic keratitis, failed to show a statistically significant improvement in cure rates compared with a placebo after four weeks of treatment. The rare eye disease damages corneal nerves, reducing sensation and the eye's ability to heal naturally. RGN-259 is an eye drop containing thymosin beta-4, a protein intended to promote tissue repair and nerve regeneration.
HLB Therapeutics said it received the preliminary results from its contract research organization on Nov. 13 and plans to analyze secondary endpoints and patient subgroup responses before deciding its next steps. As of 9:41 a.m., the stock remained at the daily lower limit of 1,635 won, down 700 won from its previous close of 2,335 won, according to Korea Exchange data.
Tags : HLBTherapeutics, HotStock, KOSDAQ, KoreanStockMarket, ClinicalTrial, Phase3Trial, RGN259, NeurotrophicKeratitis, Biotechnology
Copyright ⓒ Aju Press All rights reserved.